ClinicalRM tests convalescent plasma therapy for Ebola treatment

Monday, December 15, 2014

Clinical Research Management (ClinicalRM), a full-service CRO with headquarters in Ohio, has announced that the clinical trial evaluating the safety and efficacy of Ebola convalescent plasma (ECP) for the treatment of Ebola virus disease (EVD) in Liberia has commenced. The first donor survivors at the ELWA Hospital 2 unit in Monrovia, Liberia have undergone plasmapheresis. The donated convalescent plasma was transferred to a Liberian patient with EVD in an effort to help them combat this disease. The ClinicalRM trial is being funded through a grant from the Bill & Melinda Gates Foundation.

[Read More]

Gates Foundation to support Ebola-affected countries, accelerate treatment evaluation

Monday, November 24, 2014

The Bill & Melinda Gates Foundation, based in Seattle, Wash., will be supporting efforts in Guinea and other Ebola-affected countries to scale up the production and evaluation of convalescent plasma and other convalescent blood products as potential therapies for people infected with the Ebola virus. Various drug candidates also will be evaluated, including the experimental antiviral drug brincidofovir.

[Read More]

ClinicalRM, Ohio Clinical Trials Collaborative partner

Wednesday, June 25, 2014

CRO ClinicalRM and the Ohio Clinical Trials Collaborative (OCTC) have announced a co-marketing partnership offering joint services for clinical trials of new biologics, drugs and medical devices. The relationship will serve the organizations’ mutual customers with a full spectrum of development services including access to a network of veteran investigators, patient population identification, clinical operations and guidance on medical/regulatory affairs.

[Read More]

ClinicalRM awarded BARDA contract

Thursday, March 13, 2014

Clinical Research Management (ClinicalRM), a full-service CRO providing support for basic and applied research, clinical trials and regulatory support, has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA). With this contract award, ClinicalRM becomes part of a clinical studies network being established by BARDA to support development of vaccines, drugs and diagnostics, known as medical countermeasures, needed to protect health and potentially save lives in public health emergencies. The network will provide clinical services in support of adequate and well-controlled phase I through IV clinical trials or trials during a public health emergency, and will support the evaluation of chemical, biological, radiological, nuclear, pandemic influenza and emerging infectious disease medical countermeasures.

[Read More]

ClinicalRM awarded two contracts to support Navy Medical Research Center

Friday, September 30, 2011

Clinical Research Management (ClinicalRM), a full-service contract research organization providing services for basic and applied research, clinical trials, and regulatory support, was awarded two contracts by the Navy Medical Research Center (NMRC) under its Omnibus III program. The awards are for the provision resources in support of NMRC, including: providing an infrastructure of personnel, materials, equipment, facilities, science, and technology that will sustain an acceptable level of medical research.

[Read More]